Glazer and Omer Are New Members of National Academy of Medicine
Two Yale faculty members, Peter M. Glazer, MD, PhD; and Saad B. Omer, MBBS, MPH, PHD; have been elected to the prestigious National Academy of Medicine, the academy announced today. Founded in 1970 as the Institute of Medicine the National Academy of Medicine (NAM) is one of three academies that make up the National Academies of Sciences, Engineering, and Medicine (the National Academies) in the United States.
Juan Vasquez, MD, Vidya Puthenpura, MD, MHS, FAAP, Awarded Grants to Further Pediatric Cancer Research
Two rising young stars of pediatric cancer research at Yale Cancer Center and Yale School of Medicine were awarded research grants from Hyundai Hope on Wheels program to further their work of improving outcomes and treatment for children diagnosed with cancer.
Ensuring Bone Health for Adolescents Identifying as Transgender
With a grant from Women's Health Research at Yale, Dr. Stuart Weinzimer, in collaboration with Drs. Thomas Carpenter and Christy Olezeski, is using sophisticated methods to obtain a picture of the dynamic process of bone development in adolescents undergoing gender-affirming hormone therapy.
New technology could be game changer for people living with Type 1 diabetes
There's a new high-tech tool that could be a game-changer for people with Type 1 diabetes. Yale Principal Investigator and Associate Professor in Pediatrics (Endocrinology), Jennifer Sherr, discusses the Omnipod 5, which monitors insulin levels through a sensor on the skin, then sends the insulin directly through the patch as needed.Source: WNYT.com
Four Yale Researchers Honored at the 2022 Association for Clinical and Translational Science Awards
The collaboration that advanced the discovery of ketamine as a treatment for depression was among four Yale award winners at the Association for Clinical and Translational Science (ACTS) annual meeting held in Chicago from April 20 through 22.
Linda Coleman accepts appointment to the Board of Directors, Association for the Accreditation of Human Research Protection Programs
Linda Coleman, JD, the Director of the Yale Human Research Protection Program (HRPP), which assists Yale University in meeting its ethical and regulatory obligations for the protection of human research participants, has accepted an appointment to the Board of Directors of the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
For child care programs, masking helped minimize closures, study shows
A new Yale study that followed more than 6,600 child care professionals across the 50 states found that programs practicing child masking early in the pandemic saw lower rates of program interruption compared with those that did not.
YCCI’s Tesheia Johnson Appointed to CTSA Steering Committee
The National Center for Advancing Translational Sciences (NCATS) has announced the new members of its Clinical and Translational Science Awards (CTSA) Program steering committee, including Yale School of Medicine Director of Clinical Research and Yale Center for Clinical Investigation (YCCI) Chief Operating Officer Tesheia Johnson, MBA, MHS. The steering committee provides direction to NCATS and the more than 60 CTSA-funded institutions around the country, including Yale.
Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy
A new analysis of the EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), found at 30 weeks improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo.Source: DAIC
Strategies to accelerate diagnosis and treatment of rare cardiovascular diseases
The current landscape for patients with rare cardiovascular disease has shifted. Using genome sequencing Yale physician-scientists have begun to elucidate the pathophysiology of genetic disorders and develop treatment guidelines and recommendations.
Trial supports first specific treatment for obstructive hypertrophic cardiomyopathy
Mavacamten improves heart function and symptoms in patients with obstructive hypertrophic cardiomyopathy, according to results of the EXPLORER-HCM trial presented in a Hot Line session today at ESC Congress 2020.Source: Medical Xpress